Home » Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development

Proteome Sciences and Icon Collaborate on Mass Spec Assays for Pharma Biomarker Development

Nov 19, 2010
Premium

This story originally ran on Nov. 18.

By Adam Bonislawski

Proteome Sciences announced this week that it is partnering with Irish pharmaceutical services firm Icon to offer biomarker discovery and validation work in support of drug development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

What's Popular?

In Proteomics & Protein Research

  1. Late-Onset Preeclampsia Markers Proposed From Proteomic Study

  2. FDA, NCI Memorandum Indicates Growing Interest in Proteogenomics as Clinical Approach

    Premium

  3. PNNL Team Pushing Sensitivity Limits of Targeted Proteomics

    Premium

  4. Waters Q2 Revenues Grow 4 Percent

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.